最新的2期临床试验VLA15-221的结果再次展示了该候选疫苗可激发针对覆盖的六种血清型的显著记忆性抗体反应,这些结果在儿童(5至11岁)、青少年(12至17岁)和成人(18至65岁)参与者中均保持一致。在第二次增强接种后,高比例的参与者发生了血清转换,所有年龄组中,针对外膜蛋白A(OspA)血清型的血清转换率(SCR)均超过90%,与首次增强接种后的SCR一致。接种首次和第二次增强疫苗一个月后(即第19个月和第31个月),参与者的抗体几何平均滴度相似且维持在较高水平。
参考资料:
[1] Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine. Retrieved September 3, 2024, from https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-positive-topline-results-0
[2] Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older. Retrieved September 3, 2024, from https://www.globenewswire.com/news-release/2024/09/03/2939548/0/en/Vaxcyte-Reports-Positive-Topline-Data-from-Phase-1-2-Study-of-VAX-31-its-31-Valent-Pneumococcal-Conjugate-Vaccine-Candidate-in-Adults-Aged-50-and-Older.html
[3] Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate. Retrieved September 3, 2024, from https://www.globenewswire.com/news-release/2024/09/03/2939282/0/en/Valneva-and-Pfizer-Report-Further-Positive-Phase-2-Booster-Results-for-Lyme-Disease-Vaccine-Candidate.html
分享,点赞,在看,聚焦全球生物医药健康创新
最新的2期临床试验VLA15-221的结果再次展示了该候选疫苗可激发针对覆盖的六种血清型的显著记忆性抗体反应,这些结果在儿童(5至11岁)、青少年(12至17岁)和成人(18至65岁)参与者中均保持一致。在第二次增强接种后,高比例的参与者发生了血清转换,所有年龄组中,针对外膜蛋白A(OspA)血清型的血清转换率(SCR)均超过90%,与首次增强接种后的SCR一致。接种首次和第二次增强疫苗一个月后(即第19个月和第31个月),参与者的抗体几何平均滴度相似且维持在较高水平。
参考资料:
[1] Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine. Retrieved September 3, 2024, from https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-positive-topline-results-0
[2] Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older. Retrieved September 3, 2024, from https://www.globenewswire.com/news-release/2024/09/03/2939548/0/en/Vaxcyte-Reports-Positive-Topline-Data-from-Phase-1-2-Study-of-VAX-31-its-31-Valent-Pneumococcal-Conjugate-Vaccine-Candidate-in-Adults-Aged-50-and-Older.html
[3] Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate. Retrieved September 3, 2024, from https://www.globenewswire.com/news-release/2024/09/03/2939282/0/en/Valneva-and-Pfizer-Report-Further-Positive-Phase-2-Booster-Results-for-Lyme-Disease-Vaccine-Candidate.html
分享,点赞,在看,聚焦全球生物医药健康创新